» Articles » PMID: 30880947

Differences in Plasma Amino Acid Levels in Patients with and Without Bacterial Infection During the Early Stage of Acute Exacerbation of COPD

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2019 Mar 19
PMID 30880947
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: No consensus has been reached regarding appropriate nutritional intervention and rehabilitation during early acute exacerbation of COPD (AECOPD). Given the individual differences in symptoms of AECOPD, patients should be classified by their pathology. For example, it is known that there are differences in the inflammatory response between AECOPD with and without bacterial infection. However, there have been few reports on AECOPD from a nutritional perspective. The aim of this study was to investigate amino acid levels in patients with AECOPD.

Patients And Methods: Blood was collected from patients who were hospitalized with AECOPD and from patients with COPD that was in a stable state. We divided the patients with AECOPD into those without bacterial infection (group A) and those with bacterial infection (group B). The patients with COPD that was stable served as controls (group C). The plasma levels of 9 essential amino acids, 13 nonessential amino acids, and total amino acids were compared between the three groups.

Results: In the early stages of AECOPD, differences in plasma levels of only three amino acids (glycine, phenylalanine, and arginine) were observed between groups C and A. Differences in total amino acids and 13 amino acids were observed between groups C and B. Group B had lower levels of total amino acids and of seven amino acids (asparagine, citrulline, glutamine, histidine, methionine, serine, and threonine) compared with the other study groups.

Conclusion: The findings of this study show that amino acid levels in plasma differ in patients with AECOPD depending on whether or not bacterial infection is present. Our results suggest that specific amino acids (ie, asparagine, citrulline, glutamine, histidine, serine, and threonine) have potential utility as diagnostic markers to distinguish between bacterial and nonbacterial AECOPD.

Citing Articles

Reduced plasma glycine concentration in healthy and chronically diseased older adults: a marker of visceral adiposity?.

Deutz L, Wierzchowska-McNew R, Deutz N, Engelen M Am J Clin Nutr. 2024; 119(6):1455-1464.

PMID: 38616018 PMC: 11251212. DOI: 10.1016/j.ajcnut.2024.04.008.


Exploration of biomarkers for efficacy evaluation of traditional Chinese medicine syndromes of acute exacerbation of chronic obstructive pulmonary disease based on metabolomics.

Hailong Z, Yimei S, Yan D, Xinguang L, Jiansheng L Front Pharmacol. 2024; 15:1302950.

PMID: 38344179 PMC: 10853405. DOI: 10.3389/fphar.2024.1302950.


Jian-Ti-Kang-Yi decoction alleviates poly(I:C)-induced pneumonia by inhibiting inflammatory response, reducing oxidative stress, and modulating host metabolism.

Cui H, Wang Y, Yu B, Wu Y, Zhang G, Guo J Front Pharmacol. 2022; 13:979400.

PMID: 36147321 PMC: 9486163. DOI: 10.3389/fphar.2022.979400.


Reprogramming of Amino Acid Metabolism Differs between Community-Acquired Pneumonia and Infection-Associated Exacerbation of Chronic Obstructive Pulmonary Disease.

Arshad H, Siokis A, Franke R, Habib A, Alfonso J, Poliakova Y Cells. 2022; 11(15).

PMID: 35892580 PMC: 9330610. DOI: 10.3390/cells11152283.


Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis.

Hoult G, Gillespie D, Wilkinson T, Thomas M, Francis N BMC Pulm Med. 2022; 22(1):194.

PMID: 35549921 PMC: 9101830. DOI: 10.1186/s12890-022-01958-4.


References
1.
Gulcev M, Reilly C, Griffin T, Broeckling C, Sandri B, Witthuhn B . Tryptophan catabolism in acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016; 11:2435-2446. PMC: 5047709. DOI: 10.2147/COPD.S107844. View

2.
Collins P, Stratton R, Elia M . Nutritional support in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012; 95(6):1385-95. DOI: 10.3945/ajcn.111.023499. View

3.
Zhong Z, Wheeler M, Li X, Froh M, Schemmer P, Yin M . L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care. 2003; 6(2):229-40. DOI: 10.1097/00075197-200303000-00013. View

4.
Anthonisen N, Manfreda J, Warren C, Hershfield E, Harding G, Nelson N . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2):196-204. DOI: 10.7326/0003-4819-106-2-196. View

5.
Donaldson G, Seemungal T, Bhowmik A, Wedzicha J . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57(10):847-52. PMC: 1746193. DOI: 10.1136/thorax.57.10.847. View